New trial offers combination therapy to combat ovarian cancer

A new clinical trial is offering combination therapy to directly kill ovarian cancer cells and teach the immune system to prevent them returning.

The clinical trial is focusing on women whose ovarian cancer results from mutated BRCA genes. It combines one drug that kills the ovarian cancer cells and another that boosts the immune system in response to the dying cancer cells.

Ovarian cancer does not have obvious symptoms and no screening tests that catch it in its early stages exist. This means that ovarian cancer frequently spreads to other organs before a woman even knows she has it.

Surgery and chemotherapy can help women at the beginning of their treatment, and this served as the inspiration for trial leader Dr Sarah Adams, of the University of New Mexico Comprehensive Cancer Center, US.

The study is focusing on women with BRCA1 and BRCA2 mutations. These are genetic mutations associated with a higher risk of breast and ovarian cancers.ADNFCR-2094-ID-801832573-ADNFCR